Diagnosis and treatment of acquired factor VIII deficiency: a case report and literature review
- PMID: 36281058
- PMCID: PMC9608068
- DOI: 10.1177/03000605221132882
Diagnosis and treatment of acquired factor VIII deficiency: a case report and literature review
Abstract
Acquired haemophilia A (AHA) is a rare haemorrhagic disease characterized by spontaneous extensive subcutaneous haemorrhage and soft tissue haematoma. The activated partial thromboplastin time is significantly prolonged and cannot be corrected by normal plasma. Approximately 50% of AHA patients lack a specific aetiology, so this can easily result in a misdiagnosis. This current case report describes a 27-year-old male that presented with gingival bleeding, haematuria and haematochezia with no obvious cause. At first, it was thought that he might have experienced anticoagulant rodenticide poisoning, but the subsequent anticoagulant rodenticide test was negative. At the same time, the patient was screened for mutations associated with bleeding and coagulation diseases. Two mutations were identified: a p.Y471H mutation the plasminogen activator, tissue type (PLAT) gene; and a p.Y244Y mutation the serpin family E member 1 (SERPINE1) gene. It should be noted that patient had no previous history of thrombosis or haemorrhagic disease, which confused the diagnosis. A professional haemophilia research centre provided clarification of the diagnosis when anti-factor VIII antibodies were detected. The patient was treated with 30 mg/day prednisone orally. Multiple follow-up examinations showed continuous complete remission. No factor VIII antibodies were detected in his blood and coagulation factor VIII increased significantly.
Keywords: Bleeding disorders; acquired haemophilia A; anti-coagulation factor VIII antibody; coagulation factors; factor VIII.
Conflict of interest statement
The authors declare that there are no conflicts of interest.
Figures
References
-
- Shetty S, Bhave M, Ghosh K. Acquired hemophilia a: diagnosis, aetiology, clinical spectrum and treatment options. Autoimmun Rev 2011; 10: 311–316. - PubMed
-
- Moccia F, Tognoni E, Boccaccio P. Acquired factor VIII inhibitor associated with prostatic cancer: successful treatment with steroid and immunosuppressive therapy. Ann Ital Med Int 2000; 15: 172–176. - PubMed
-
- Gebbink MF. Tissue-type plasminogen activator-mediated plasminogen activation and contact activation, implications in and beyond haemostasis. J Thromb Haemost 2011; 9: 174–181. - PubMed
-
- Heiman M, Gupta S, Khan SS, et al.. Complete Plasminogen Activator Inhibitor 1 Deficiency. 2017. In: Adam MP, Everman DB, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK447152/. - PubMed
-
- Gagnier JJ, Kienle G, Altman DG, et al.. The CARE guidelines: consensus-based clinical case reporting guideline development. Headache 2013; 53: 1541–1547. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
